These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 175020)

  • 1. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
    Henle G; Henle W
    Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients].
    Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW
    Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia.
    Dölken G; Bross KJ; Hecht T; Brugger W; Löhr GW; Hirsch FW
    Int J Cancer; 1986 Jul; 38(1):55-9. PubMed ID: 3013785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing EBV-specific IgA in throat washings of nasopharyngeal carcinoma (NPC) patients.
    Desgranges C; De-Thé G; Ho JH; Ellouz R
    Int J Cancer; 1977 May; 19(5):627-33. PubMed ID: 193801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of virus-specific antibodies to EBV-antigens in patients with nasopharyngeal carcinoma (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1979 Dec; 58(12):911-5. PubMed ID: 231716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG and IgA antibodies to Epstein-Barr virus in nasopharyngeal carcinoma patients.
    Gong SH; Lynn TC; Yang CS
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1978 Mar; 11(1):8-15. PubMed ID: 211015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-specific serodiagnostic tests in carcinomas of the head and neck.
    Ringborg U; Henle W; Henle G; Ingimarsson S; Klein G; Silfversward C; Strander H
    Cancer; 1983 Oct; 52(7):1237-43. PubMed ID: 6309355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan.
    Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T
    Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [IgG- and IgA-antibodies to the Epstein-Barr virus in the sera of patients with nasopharyngeal carcinoma in Cuba].
    Gurtsevich VE; Ruíz García R; Cuevas J; Le Riverand Morales E; Ascue M
    Vopr Virusol; 1979; (4):392-9. PubMed ID: 225887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr-virus-specific IgA and IgG serum antibodies in nasopharyngeal carcinoma.
    Ho HC; Ng MH; Kwan HC; Chau JC
    Br J Cancer; 1976 Dec; 34(6):655-60. PubMed ID: 188437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma.
    Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C
    Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.